Apitoria Pharma Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RALOXIFENE HYDROCHLORIDE USP (NON-STERILE DRUG SUBSTANCE), with a corresponding US DMF Number 25650.
Remarkably, this DMF maintains an Active status since its submission on January 10, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 12, 2018, and payment made on September 05, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II